NASDAQ:NVCT Nuvectis Pharma (NVCT) Stock Price, News & Analysis → Biden’s $374B Giveaway Into This Sector (From DTI) (Ad) Free NVCT Stock Alerts $6.72 -0.04 (-0.59%) (As of 04/18/2024 ET) Add Compare Share Share Today's Range$6.56▼$7.0650-Day Range$6.41▼$11.0052-Week Range$6.20▼$18.65Volume80,804 shsAverage Volume54,509 shsMarket Capitalization$119.41 millionP/E RatioN/ADividend YieldN/APrice Target$21.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Nuvectis Pharma alerts: Email Address Nuvectis Pharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside212.5% Upside$21.00 Price TargetShort InterestBearish12.12% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.16Based on 3 Articles This WeekInsider TradingAcquiring Shares$51,450 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($1.52) to ($1.78) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.64 out of 5 starsMedical Sector419th out of 918 stocksPharmaceutical Preparations Industry190th out of 429 stocks 3.5 Analyst's Opinion Consensus RatingNuvectis Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageNuvectis Pharma has received no research coverage in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted12.12% of the float of Nuvectis Pharma has been sold short.Short Interest Ratio / Days to CoverNuvectis Pharma has a short interest ratio ("days to cover") of 7.6.Change versus previous monthShort interest in Nuvectis Pharma has recently increased by 5.50%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldNuvectis Pharma does not currently pay a dividend.Dividend GrowthNuvectis Pharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NVCT. Previous Next 3.4 News and Social Media Coverage News SentimentNuvectis Pharma has a news sentiment score of 1.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Nuvectis Pharma this week, compared to 1 article on an average week.Search Interest4 people have searched for NVCT on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Nuvectis Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Nuvectis Pharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $51,450.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders38.85% of the stock of Nuvectis Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions96.77% of the stock of Nuvectis Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Nuvectis Pharma are expected to decrease in the coming year, from ($1.52) to ($1.78) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nuvectis Pharma is -4.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nuvectis Pharma is -4.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNuvectis Pharma has a P/B Ratio of 9.60. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Gold Safe ExchangeThe “Perfect Storm” for GoldGold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.Click here now to download the free Precious Metals Buying Guide! About Nuvectis Pharma Stock (NASDAQ:NVCT)Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.Read More NVCT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NVCT Stock News HeadlinesMarch 20, 2024 | insidertrades.comInsider Buying: Nuvectis Pharma, Inc. (NASDAQ:NVCT) CEO Purchases 5,000 Shares of StockApril 17, 2024 | finance.yahoo.comIs Nuvectis Pharma (NASDAQ:NVCT) In A Good Position To Deliver On Growth Plans?April 19, 2024 | InvestorPlace (Ad)New crypto project uncovers 2,050% in 65 daysDuring the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.April 13, 2024 | americanbankingnews.comNuvectis Pharma, Inc. (NASDAQ:NVCT) to Post Q1 2024 Earnings of ($0.39) Per Share, HC Wainwright ForecastsApril 10, 2024 | americanbankingnews.comNuvectis Pharma (NASDAQ:NVCT) Shares Down 1.5% April 8, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Nuvectis Pharma (NVCT) and Invivyd (IVVD)April 8, 2024 | finanznachrichten.deNuvectis Pharma, Inc.: Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell LinesApril 8, 2024 | markets.businessinsider.comNuvectis Pharma: Data Confirms Robust Activity Of NXP900 - Quick FactsApril 19, 2024 | InvestorPlace (Ad)New crypto project uncovers 2,050% in 65 daysDuring the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.April 8, 2024 | finance.yahoo.comNuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell LinesApril 8, 2024 | globenewswire.comNuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell LinesApril 2, 2024 | investorplace.com5 Healthcare Stocks to Buy for 2024March 21, 2024 | finance.yahoo.comInsider Buys Additional US$51k In Nuvectis Pharma StockMarch 19, 2024 | globenewswire.comNuvectis Pharma Announces Upcoming Presentations at the 2024 American Association for Cancer Research MeetingMarch 15, 2024 | msn.comNuvectis reports initial data from Phase Ib ovarian cancer trialMarch 15, 2024 | marketwatch.comNuvectis Pharma Shares Rise 11% After Positive Preliminary Data for Cancer TreatmentMarch 15, 2024 | globenewswire.comNuvectis Pharma to Present at the 36th Annual Roth ConferenceMarch 14, 2024 | globenewswire.comNuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian CancerMarch 6, 2024 | investorplace.comNVCT Stock Earnings: Nuvectis Pharma Misses EPS for Q4 2023March 5, 2024 | finance.yahoo.comNuvectis Pharma Inc (NVCT) Reports Increased Net Loss in FY 2023 Despite Clinical ProgressFebruary 19, 2024 | finance.yahoo.comNuvectis Pharma, Inc. (NASDAQ:NVCT) insiders have significant skin in the game with 67% ownershipFebruary 9, 2024 | morningstar.comNuvectis Pharma Inc NVCTFebruary 9, 2024 | finance.yahoo.comCorrection: Nuvectis Pharma Announces Participation at Upcoming Investor ConferencesJanuary 3, 2024 | finance.yahoo.comNuvectis Pharma to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceDecember 18, 2023 | finance.yahoo.comNuvectis Pharma, Inc. Announces a Collaboration with Mayo Clinic to Evaluate NXP800 in an Investigator-Sponsored Clinical Trial in CholangiocarcinomaNovember 25, 2023 | finance.yahoo.comNuvectis Pharma Insiders Added US$3.75m Of Stock To Their HoldingsNovember 8, 2023 | msn.comNuvectis Pharma GAAP EPS of -$0.37See More Headlines Receive NVCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nuvectis Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/05/2024Today4/19/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:NVCT CUSIPN/A CIK1875558 Webwww.nuvectis.com Phone201-614-3150FaxN/AEmployees13Year FoundedN/APrice Target and Rating Average Stock Price Target$21.00 High Stock Price Target$21.00 Low Stock Price Target$21.00 Potential Upside/Downside+212.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.43) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-22,260,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-144.80% Return on Assets-107.80% Debt Debt-to-Equity RatioN/A Current Ratio2.75 Quick Ratio2.75 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.70 per share Price / Book9.60Miscellaneous Outstanding Shares17,770,000Free Float10,866,000Market Cap$119.41 million OptionableNot Optionable Beta0.28 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Ron Bentsur M.B.A. (Age 58)Co-Founder, Chairman, CEO & President Comp: $851.61kDr. Enrique Poradosu Ph.D. (Age 57)Co-Founder, Executive VP, Chief Scientific & Business Officer Comp: $549.07kMr. Shay Shemesh (Age 40)Co-Founder, Executive VP, Chief Development & Operations Officer Comp: $529.27kMr. Michael Carson CPA (Age 47)Vice President of Finance Key CompetitorsRepare TherapeuticsNASDAQ:RPTXOptiNoseNASDAQ:OPTNVistagen TherapeuticsNASDAQ:VTGNCytomX TherapeuticsNASDAQ:CTMXEliem TherapeuticsNASDAQ:ELYMView All CompetitorsInsiders & InstitutionsBlue Zone Wealth Advisors LLCBought 14,350 shares on 4/18/2024Ownership: 0.081%Ron BentsurBought 5,000 shares on 3/18/2024Total: $51,450.00 ($10.29/share)Vanguard Group Inc.Bought 3,149 shares on 3/11/2024Ownership: 1.656%GSA Capital Partners LLPBought 27,313 shares on 2/16/2024Ownership: 0.158%Vanguard Group Inc.Bought 3,149 shares on 2/15/2024Ownership: 1.698%View All Insider TransactionsView All Institutional Transactions NVCT Stock Analysis - Frequently Asked Questions Should I buy or sell Nuvectis Pharma stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Nuvectis Pharma in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" NVCT shares. View NVCT analyst ratings or view top-rated stocks. What is Nuvectis Pharma's stock price target for 2024? 1 brokerages have issued twelve-month price objectives for Nuvectis Pharma's stock. Their NVCT share price targets range from $21.00 to $21.00. On average, they anticipate the company's stock price to reach $21.00 in the next year. This suggests a possible upside of 212.5% from the stock's current price. View analysts price targets for NVCT or view top-rated stocks among Wall Street analysts. How have NVCT shares performed in 2024? Nuvectis Pharma's stock was trading at $8.34 at the start of the year. Since then, NVCT shares have decreased by 19.4% and is now trading at $6.72. View the best growth stocks for 2024 here. When is Nuvectis Pharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our NVCT earnings forecast. How were Nuvectis Pharma's earnings last quarter? Nuvectis Pharma, Inc. (NASDAQ:NVCT) released its quarterly earnings results on Tuesday, March, 5th. The company reported ($0.41) earnings per share for the quarter, missing analysts' consensus estimates of ($0.40) by $0.01. When did Nuvectis Pharma IPO? Nuvectis Pharma (NVCT) raised $19 million in an initial public offering (IPO) on Friday, February 4th 2022. The company issued 3,200,000 shares at a price of $5.00-$7.00 per share. Who are Nuvectis Pharma's major shareholders? Nuvectis Pharma's stock is owned by a variety of institutional and retail investors. Top institutional investors include Blue Zone Wealth Advisors LLC (0.08%). Insiders that own company stock include Enrique Poradosu, Kenneth Hoberman, Marlio Charles Mosseri, Ron Bentsur and Shay Shemesh. View institutional ownership trends. How do I buy shares of Nuvectis Pharma? Shares of NVCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NVCT) was last updated on 4/19/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingBiden’s $374B Giveaway Into This SectorDTIForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressHe Is Giving Away BitcoinCrypto Swap ProfitsThe #1 Crypto for 2024InvestorPlaceHow Biden has already won 2024Porter & CompanyUrgent alert: open this for a huge profit potentialTimothy Sykes Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuvectis Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.